Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

AlzeCure Pharma

2.40 SEK

+11.63 %

Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+11.63 %
+12.68 %
-32.01 %
-26.36 %
+119.64 %
+124.52 %
-39.68 %
-70.65 %
-74.65 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
275.79M SEK
Turnover
82.13K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2.
2026

Annual report '25

5.5.
2026

Interim report Q1'26

14.5.
2026

General meeting '26

All
Press releases
3rd party
ShowingAll content types
Press release12/3/2025, 9:00 AM

AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer's disease

AlzeCure Pharma
Press release11/14/2025, 11:35 AM

Redeye: AlzeCure Pharma (Q3 Review) - Clinical phase IIa study in focus

AlzeCure Pharma
Regulatory press release11/11/2025, 7:00 AM

AlzeCure publishes its interim report for January – September 2025

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release10/14/2025, 6:00 AM

Response letter to previous article published about Alzstatin's unique mode of action against Alzheimer's

AlzeCure Pharma
Press release10/7/2025, 8:00 AM

AlzeCure Pharma to present at Redeye Neurology Day on October 15

AlzeCure Pharma
Press release9/8/2025, 8:00 AM

Positive study results with TrkA-NAM ACD137 against knee osteoarthritis presented at pain conference NeuPSIG 2025

AlzeCure Pharma
Press release9/4/2025, 8:00 AM

Data from AlzeCure's pain project ACD440 presented at the NeuPSIG 2025 pain conference

AlzeCure Pharma
Press release8/27/2025, 9:58 AM

Redeye: AlzeCure Q2 - Prepares for clinical studies

AlzeCure Pharma
Regulatory press release8/26/2025, 6:00 AM

AlzeCure publishes its interim report for January – June 2025

AlzeCure Pharma
Press release8/20/2025, 8:00 AM

AlzeCure appoints Cecilia Wadell as new Head of Development

AlzeCure Pharma
Press release8/19/2025, 8:00 AM

AlzeCure Pharma livestreams event about the pain project ACD440 and the opportunities within orphan drugs

AlzeCure Pharma
Press release8/5/2025, 8:00 AM

New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference

AlzeCure Pharma
Press release7/29/2025, 6:00 AM

New scientific article published on positive clinical results with Painless ACD440 against neuropathic pain

AlzeCure Pharma
Regulatory press release7/24/2025, 9:00 AM

AlzeCure's rights issue oversubscribed and the company resolves on a directed share issue under the framework of an overallotment option

AlzeCure Pharma
Regulatory press release7/24/2025, 8:00 AM

AlzeCure's rights issue oversubscribed according to preliminary results

AlzeCure Pharma
Regulatory press release7/23/2025, 7:50 PM

AlzeCure's rights issue oversubscribed according to preliminary results

AlzeCure Pharma
Press release7/21/2025, 8:00 AM

AlzeCure presents ACD440 at the NeuPSIG 2025 pain conference

AlzeCure Pharma
Regulatory press release7/16/2025, 9:20 AM

AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue

AlzeCure Pharma
Regulatory press release7/15/2025, 1:37 PM

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma
Regulatory press release7/7/2025, 12:50 PM

AlzeCure Pharma publishes amended Information document regarding rights issue

AlzeCure Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.